Establishing whether a CNS drug reaches the brain, changes brain function and engages its target is a critical challenge in early development. In this webinar, Dr Graham Wood and Dr Sally Dowen will present an evidence ladder for selecting and combining CNS assessments to inform Phase 2 decisions.
Drawing on more than 45 years of combined experience and practical case studies, the session will climb from CSF sampling and biomarkers, through fMRI, qEEG and functional testing, to PET. We will discuss the scientific and operational considerations that shape successful protocols, including sampling strategies, imaging selection, sleep studies and participant recruitment.
The webinar will also explore how adaptive and multipart protocols combine populations, dosing stages and CNS assessments in one submission. Discussion of psychedelic trials will address their distinct regulatory, clinical and operational requirements. Attendees will learn to climb only as high as the Phase 2 decision requires, weighing each assessment against its cost, participant burden and operational risk.
Learning outcomes:
- Select the right CNS assessments: Understand how CSF sampling, fMRI, qEEG, functional testing and PET show brain exposure, functional effects and target engagement.
- Translate scientific objectives into practical protocols: Explore key design and delivery considerations for CSF sampling, functional testing and imaging studies.
- Build flexibility into early development: Discover how adaptive and multipart protocols can integrate populations, dosing stages and CNS assessments to improve program efficiency.
- Prepare for complex study delivery: Understand recruitment strategies for healthy participants and CNS patient populations, alongside the distinct regulatory, clinical and operational requirements of psychedelic trials.